SCS Traditional denied as duplicate or overlapping therapy by eviCore healthcare?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What eviCore healthcare typically requires
NACC-aligned. Conservative therapy >=6 weeks, BHE clearance, >=50% trial relief documented for SCS implant.
What works in the appeal
Submit eviCore PA retroactively with full clinical. Psychologist letter explicitly stating 'appropriate candidate per NACC criteria.' Trial diary: daily NRS, ODI pre/post, analgesic reduction, patient global impression.
The eviCore healthcare angle on SCS Traditional
## Why eviCore Denied This — and Why Duplicate-Therapy Denials Are Commonly Reversed
A duplicate-therapy denial for traditional (conventional, tonic-mode) spinal cord stimulation from eviCore typically means that eviCore's review found that another currently approved or active therapy is considered to address the same clinical need. This most often arises when a patient has an existing SCS system, is receiving another neuromodulation therapy, or when records show an overlapping intervention. These denials are frequently overturned because the clinical distinction between therapies — or the reason one is insufficient — is not captured in claims data.
## Why This Denial Is Clinically Weak
Medical necessity decisions must be based on the patient's actual clinical situation, not on a pattern-match of billing codes. If you have an existing SCS device that has lost efficacy, requires replacement due to hardware failure, or is being revised to address coverage gaps, that is not a duplication — it is medically necessary maintenance or revision of an established therapy. Your appeal must clearly document the clinical distinction.
## Your Federal Appeal Rights
eviCore functions as the utilization management agent for the underlying insurer. The appeal process runs through that insurer's formal appeal pathway. After exhausting internal appeals, fully-insured ACA plan members may request external review under ACA §2719; ERISA self-funded plan participants are entitled to a full-and-fair review under ERISA §503. File for external review within four months of the final internal denial. Expedited review (72-hour turnaround) is available for urgent cases.
## Appeal Timeline
1. File Level 1 internal appeal with the underlying insurer, explicitly requesting that the eviCore determination be reconsidered. 2. Request a peer-to-peer call between the implanting physician and the eviCore medical director — document the outcome. 3. Escalate to external review if unresolved.
## Documentation to Gather
- Treating physician letter: explains the clinical distinction between the current and proposed therapy, documenting why the proposed procedure is not duplicative.
- Device and programming records: documentation of the existing system, its coverage parameters, efficacy history, and the clinical reason it does not address the current need.
- Diagnostic and functional records: objective documentation of persistent symptoms despite current therapy.
- Hardware documentation: if a replacement or revision is sought, records showing device failure, battery depletion, or lead migration.
## Criteria-Mapping Structure
Obtain eviCore's applicable clinical guideline for SCS (they publish these online). List each coverage criterion. For each, document the specific clinical fact that satisfies it. For the duplicate-therapy concern specifically, include a dedicated paragraph explaining the clinical distinction — why the proposed therapy addresses a need the existing therapy does not.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →